Center for Scientific Review; Notice of Closed Meeting, 53479-53480 [2011-21765]
Download as PDF
<![CDATA[
53479
Federal Register / Vol. 76, No. 166 / Friday, August 26, 2011 / Notices
revised and renames what was
previously known as the NHSC Uniform
Data System (UDS) Report. The survey
is completed annually by sites that
receive an NHSC provider and are not
currently receiving HRSA grant support.
The NHSC Site Survey provides
information that is utilized for
monitoring and evaluating program
operations and effectiveness, in addition
to accurately reporting the scope of
supported activities.
The annual estimate of burden is as
follows:
Instrument
Number of
respondents
Responses
per
respondent
Total
responses
Hours per
response
Total burden
hours
NHSC Site Survey ...............................................................
1200
1
1200
27
32,400
E-mail comments to
paperwork@hrsa.gov or mail the HRSA
Reports Clearance Officer, Room 10–33,
Parklawn Building, 5600 Fishers Lane,
Rockville, MD 20857. Written comments
should be received within 60 days of
this notice.
Dated: August 22, 2011.
Reva Harris,
Acting Director, Division of Policy and
Information Coordination.
[FR Doc. 2011–21942 Filed 8–25–11; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
emcdonald on DSK2BSOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Community-Level Health Promotion Study
Section.
Date: September 26–27, 2011.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Jacinta Bronte-Tinkew,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164,
MSC 7770, Bethesda, MD 20892. (301) 806–
0009. brontetinkewjm@csr.nih.gov.
VerDate Mar<15>2010
19:37 Aug 25, 2011
Jkt 223001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Biology and Genetics.
Date: September 27–28, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting.)
Contact Person: Nywana Sizemore, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804, Bethesda, MD 20892. 301–435–
1718. sizemoren@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Development—2
Study Section.
Date: September 29–30, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: Rass M Shayiq, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 435–
2359, shayiqr@csr.nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Modeling and Analysis of Biological
Systems Study Section.
Date: September 29, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Raymond Jacobson, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5858,
MSC 7849, Bethesda, MD 20892, 301–996–
7702, jacobsonrh@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Kidney, Nutrition, Obesity and Diabetes
Study Section.
Date: September 30, 2011.
Time: 7 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Orlando World Center Marriott,
8701 World Center Drive, Orlando, FL 32821.
Contact Person: Fungai Chanetsa, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3135,
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
MSC 7770, Bethesda, MD 20892. 301–408–
9436. fungai.chanetsa@nih.hhs.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cellular and
Molecular Neuroscience.
Date: September 30, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: Laurent Taupenot, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4811,
MSC 7850, Bethesda, MD 20892. 301–435–
1203. taupenol@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21767 Filed 8–25–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the public
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\26AUN1.SGM
26AUN1
53480
Federal Register / Vol. 76, No. 166 / Friday, August 26, 2011 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Academic
Research Enhancement Award (Parent 15).
Date: September 8, 2011.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: Monica Basco, PhD,
Scientific Review Officer,Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 3220, MSC 7808,
Bethesda, MD 20892, 301–496–7010,
bascoma@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 19, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21765 Filed 8–25–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Conjugate Vaccines Against
B. anthracis (Anthrax) and Monoclonal
Antibodies Against Anthrax
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the following
invention as embodied in the following
patent applications: (1) E–146–2004/0,
Purcell et al., ‘‘Monoclonal Antibodies
That Neutralize Anthrax Protective
Antigen (PA) Toxin’’, U.S. Patent
Application Number 60/639,074, filed
on December 22, 2004, PCT Application
Number PCT/US2005/046/790, filed on
December 21, 2005, and U.S. Patent
Application Number 11/793,735, filed
on December 8, 2009, (2) E–123–2007/
0, Purcell et al., ‘‘Monoclonal
Antibodies that Neutralize B. anthracis
Protective Antigen (PA), Lethal Factor
(LF) and Edema Factor (EF)’’, U.S.
Patent Application Number 60/903,022,
filed on February 23, 2007, PCT
emcdonald on DSK2BSOYB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
19:37 Aug 25, 2011
Jkt 223001
Application Number PCT/US2008/
054609, filed on February 21, 2008, and
U.S. Patent Application Number 12/
528,427, filed on August 24, 2009, and
European Patent Application Number
08730415.0, filed on September 23,
2009, (3) E–125–2008/0, Purcell et al.,
‘‘Monoclonal Antibodies That React
With the Capsule of Bacillus anthracis’’,
U.S. Patent Application Number 61/
116,222, filed on November 19, 2008,
PCT Application Number PCT/US2009/
065198, filed on November 19, 2009,
and U.S. Patent Application Number 13/
130,044, filed on May 18, 2011, (4) E–
343–2002/0, Schneerson et al.,
‘‘gammaPGA Conjugates for Eliciting
Immune Responses Directed Against
Bacillus anthracis and Other Bacilli’’,
U.S. Patent Application Number 60/
476,598, filed on June 5, 2003, PCT
Application Number PCT/US2004/
17736, filed on June 4, 2004, U.S. Patent
Application Number 10/559,825, filed
December 2, 2005, now U.S. Patent
Number 7,803,386, European Patent
Application Number 04754360.8, filed
June 4, 2004, Canadian Patent
Application Number 2,528,067, filed
June 4, 2004, and Australian Patent
Application Number 2004252091, filed
June 4, 2004, now Australian Patent
Number 2004252091, and (5) E–040–
2005/0, Schneerson et al., ‘‘Methods for
Preparing Immunogenic Conjugates’’,
U.S. Patent Application Number 11/
005,851, filed on December 6, 2004,
now U.S. Patent Number 7,625,736, PCT
Application Number PCT/US2005/
19678, filed June 3, 2005, European
Patent Application Number 05758048.2,
filed June 3, 2005, now European Patent
Number 1765394 (rights were validated
in Germany (Patent Number
602005015855), France (Patent Number
1765394), Great Britain (Patent Number
1765394), and Ireland (Patent Number
1765394)), Indian Patent Application
Number 7703/DELNP/2006, filed June 3,
2005, Chinese Patent Application
Number 200580018108.2, filed June 3,
2005, Australian Patent Application
Number 2005249571, filed June 3, 2005,
now Australian Patent Number
2005249571, Canadian Patent
Application Number 2,568,364, filed
June 3, 2005, and U.S. Patent
Application Number 12/582,420, filed
October 20, 2009, to Biologics Resources
LLC, having a place of business in
Boyds, Maryland, United States of
America. The patent rights in these
inventions have been assigned to the
United States of America.
Only written comments and/or
application for a license which are
received by the NIH Office of
DATES:
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
Technology Transfer on or before
September 26, 2011 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; E-mail:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
SUPPLEMENTARY INFORMATION: Anthrax,
whether resulting from natural or
bioterrorist-associated exposure, is a
constant threat to human health. The
lethality of anthrax is primarily the
result of the effects of anthrax toxin,
which has 3 components: a receptorbinding protein known as ‘‘protective
antigen’’ (PA) and 2 catalytic proteins
known as ‘‘lethal factor’’ (LF) and
‘‘edema factor’’ (EF). Although
production of an efficient anthrax
vaccine is an ultimate goal, the benefits
of vaccination can be expected only if
a large proportion of the population at
risk is immunized. In contrast, passive
administration of neutralizing human or
chimpanzee monoclonal antibody to a
subject at risk for anthrax or exposed to
anthrax could provide immediate
efficacy for emergency prophylaxis
against or treatment of anthrax.
The methods and compositions of
these inventions provide a means for
prevention and/or therapy of B.
anthracis (anthrax) infection by
immunization with conjugate vaccines
against anthrax and/or passive
immunization with monoclonal
antibodies against B. anthracis.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published Notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
The fields of use may be limited to (1)
monoclonal antibodies against B.
anthracis (anthrax) for use in humans
and (2) B. anthracis conjugate vaccines
for use in humans.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
E:\FR\FM\26AUN1.SGM
26AUN1
]]>Agencies
[Federal Register Volume 76, Number 166 (Friday, August 26, 2011)]
[Notices]
[Pages 53479-53480]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-21765]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting. The meeting will be closed to the public in accordance with
the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 53480]]
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Academic Research Enhancement Award (Parent 15).
Date: September 8, 2011.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone Conference Call.)
Contact Person: Monica Basco, PhD, Scientific Review
Officer,Center for Scientific Review, National Institutes of Health,
6701 Rockledge Drive, Room 3220, MSC 7808, Bethesda, MD 20892, 301-
496-7010, bascoma@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: August 19, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-21765 Filed 8-25-11; 8:45 am]
BILLING CODE 4140-01-P
